LGND - Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
IEX Last Trade
105.63
-0.230 -0.218%
Share volume: 113,893
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$105.86
-0.23
-0.22%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-08 | 2023-02-28 | 2023-05-08 | 2023-08-09 | 2023-11-09 | 2024-02-29 | 2024-05-08 | |
| Total revenue | 57.419 M | 66.088 M | 27.045 M | 43.979 M | 26.366 M | 32.868 M | 28.101 M | 30.978 M | |
| Cost of revenue | 12.361 M | 14.153 M | 21.614 M | 3.717 M | 1.669 M | 3.485 M | 1.641 M | 2.882 M | |
| Gross profit | 45.058 M | 51.935 M | 5.431 M | 40.262 M | 24.697 M | 29.383 M | 26.460 M | 28.096 M | |
| 15.26% | -89.54% | 641.34% | -38.66% | 18.97% | -9.95% | 6.18% | |||
| Operating expenses | 33.703 M | 39.481 M | -5.527 M | 17.518 M | 18.141 M | 20.188 M | 21.480 M | 16.922 M | |
| Selling general and admin | 14.585 M | 17.445 M | 19.852 M | 10.855 M | 11.287 M | 14.656 M | 15.992 M | 10.951 M | |
| Research and development | 19.118 M | 22.036 M | -25.379 M | 6.663 M | 6.854 M | 5.532 M | 5.488 M | 5.971 M | |
| Total expenses | 57.888 M | 65.452 M | 14.869 M | 29.774 M | 28.349 M | 31.911 M | 31.459 M | 27.990 M | |
| 13.07% | -77.28% | 100.24% | -4.79% | 12.56% | -1.42% | -11.03% | |||
| Operating income | -469.000 K | 636.000 K | 12.176 M | 14.205 M | -1.983 M | 957.000 K | -3.358 M | 2.988 M | |
| Ebit | -2.378 M | -287.000 K | 27.885 M | 53.738 M | 2.008 M | -12.227 M | -33.698 M | 113.760 M | |
| Pretax income | -636.000 K | 857.000 K | 55.930 M | 55.536 M | 3.171 M | -12.144 M | 17.097 M | 113.447 M | |
| -234.75% | 6,426.25% | -0.70% | -94.29% | -482.97% | -240.79% | 563.55% | |||
| Income tax | 259.000 K | 453.000 K | 45.273 M | 11.922 M | 881.000 K | -1.871 M | -1.091 M | 27.308 M | |
| Net income basic | -895.000 K | 404.000 K | -17.485 M | 41.949 M | 2.290 M | -10.273 M | 18.188 M | 86.139 M | |
| 145.14% | -4,427.97% | 339.91% | -94.54% | -548.60% | 277.05% | 373.60% | |||
| Net income | -895.000 K | 404.000 K | -17.485 M | 41.949 M | 2.290 M | -10.273 M | 18.188 M | 86.139 M | |
| 145.14% | -4,427.97% | 339.91% | -94.54% | -548.60% | 277.05% | 373.60% |